KR20050112498A - 세포 내 침투를 촉진하는 지방족 모노아민 또는 양이온성중합체를 포함하는 수화층판상 또는 리포좀, 그것의스크리닝 방법 및 이를 포함하는 화장료 혹은 약제학적조성물 - Google Patents
세포 내 침투를 촉진하는 지방족 모노아민 또는 양이온성중합체를 포함하는 수화층판상 또는 리포좀, 그것의스크리닝 방법 및 이를 포함하는 화장료 혹은 약제학적조성물 Download PDFInfo
- Publication number
- KR20050112498A KR20050112498A KR1020040104333A KR20040104333A KR20050112498A KR 20050112498 A KR20050112498 A KR 20050112498A KR 1020040104333 A KR1020040104333 A KR 1020040104333A KR 20040104333 A KR20040104333 A KR 20040104333A KR 20050112498 A KR20050112498 A KR 20050112498A
- Authority
- KR
- South Korea
- Prior art keywords
- liposomes
- substance
- penetration
- liposome
- hydrated
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 203
- 230000035515 penetration Effects 0.000 title claims abstract description 91
- 239000000126 substance Substances 0.000 title claims abstract description 75
- 239000002537 cosmetic Substances 0.000 title claims abstract description 42
- 229920006317 cationic polymer Polymers 0.000 title claims abstract description 10
- 230000003834 intracellular effect Effects 0.000 title claims description 49
- 238000000034 method Methods 0.000 title claims description 35
- 238000012216 screening Methods 0.000 title claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 229920002873 Polyethylenimine Polymers 0.000 claims abstract description 64
- 230000036571 hydration Effects 0.000 claims abstract description 34
- 238000006703 hydration reaction Methods 0.000 claims abstract description 34
- 230000001737 promoting effect Effects 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 23
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims description 71
- 239000000463 material Substances 0.000 claims description 55
- 210000004027 cell Anatomy 0.000 claims description 47
- 235000010469 Glycine max Nutrition 0.000 claims description 36
- 244000068988 Glycine max Species 0.000 claims description 34
- 230000000694 effects Effects 0.000 claims description 33
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 26
- 210000002950 fibroblast Anatomy 0.000 claims description 26
- -1 pentafluorobenzoylamino fluorescein Chemical compound 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 20
- 235000018102 proteins Nutrition 0.000 claims description 19
- 230000003013 cytotoxicity Effects 0.000 claims description 18
- 231100000135 cytotoxicity Toxicity 0.000 claims description 18
- 125000002091 cationic group Chemical group 0.000 claims description 17
- 108010073771 Soybean Proteins Proteins 0.000 claims description 14
- 235000021307 Triticum Nutrition 0.000 claims description 14
- 229940001941 soy protein Drugs 0.000 claims description 14
- 229940046009 vitamin E Drugs 0.000 claims description 14
- 239000011709 vitamin E Substances 0.000 claims description 14
- 229930003427 Vitamin E Natural products 0.000 claims description 13
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 13
- 235000019165 vitamin E Nutrition 0.000 claims description 13
- 244000303965 Cyamopsis psoralioides Species 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 10
- 230000006907 apoptotic process Effects 0.000 claims description 10
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 10
- 239000000787 lecithin Substances 0.000 claims description 10
- 229940067606 lecithin Drugs 0.000 claims description 10
- 235000010445 lecithin Nutrition 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 240000007594 Oryza sativa Species 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 7
- 235000007164 Oryza sativa Nutrition 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 229920001436 collagen Polymers 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 235000009566 rice Nutrition 0.000 claims description 7
- 230000002087 whitening effect Effects 0.000 claims description 7
- 102000011782 Keratins Human genes 0.000 claims description 6
- 108010076876 Keratins Proteins 0.000 claims description 6
- 108010064851 Plant Proteins Proteins 0.000 claims description 6
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 6
- 239000005018 casein Substances 0.000 claims description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 6
- 235000021240 caseins Nutrition 0.000 claims description 6
- 235000012907 honey Nutrition 0.000 claims description 6
- 229920005615 natural polymer Polymers 0.000 claims description 6
- 235000021118 plant-derived protein Nutrition 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 229960000271 arbutin Drugs 0.000 claims description 5
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 5
- 235000005487 catechin Nutrition 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 claims description 4
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 claims description 4
- PLZVEHJLHYMBBY-UHFFFAOYSA-N Tetradecylamine Chemical compound CCCCCCCCCCCCCCN PLZVEHJLHYMBBY-UHFFFAOYSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 231100000433 cytotoxic Toxicity 0.000 claims description 4
- 230000001472 cytotoxic effect Effects 0.000 claims description 4
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 claims description 4
- 238000004043 dyeing Methods 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- 239000012460 protein solution Substances 0.000 claims description 4
- 150000003408 sphingolipids Chemical class 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 229920001059 synthetic polymer Polymers 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- ABVVEAHYODGCLZ-UHFFFAOYSA-N tridecan-1-amine Chemical compound CCCCCCCCCCCCCN ABVVEAHYODGCLZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- JPZYXGPCHFZBHO-UHFFFAOYSA-N 1-aminopentadecane Chemical compound CCCCCCCCCCCCCCCN JPZYXGPCHFZBHO-UHFFFAOYSA-N 0.000 claims description 3
- 244000060011 Cocos nucifera Species 0.000 claims description 3
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 3
- 230000002225 anti-radical effect Effects 0.000 claims description 3
- 150000001765 catechin Chemical class 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000000118 hair dye Substances 0.000 claims description 3
- 239000005445 natural material Substances 0.000 claims description 3
- QFKMMXYLAPZKIB-UHFFFAOYSA-N undecan-1-amine Chemical compound CCCCCCCCCCCN QFKMMXYLAPZKIB-UHFFFAOYSA-N 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 claims description 2
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 claims description 2
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 2
- 244000105624 Arachis hypogaea Species 0.000 claims description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 2
- 235000018262 Arachis monticola Nutrition 0.000 claims description 2
- 235000005881 Calendula officinalis Nutrition 0.000 claims description 2
- 244000025254 Cannabis sativa Species 0.000 claims description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 2
- 241000219130 Cucurbita pepo subsp. pepo Species 0.000 claims description 2
- 235000003954 Cucurbita pepo var melopepo Nutrition 0.000 claims description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 2
- 229920002079 Ellagic acid Polymers 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 244000020551 Helianthus annuus Species 0.000 claims description 2
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 241000446313 Lamella Species 0.000 claims description 2
- 235000004431 Linum usitatissimum Nutrition 0.000 claims description 2
- 240000006240 Linum usitatissimum Species 0.000 claims description 2
- 241000219745 Lupinus Species 0.000 claims description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 2
- 244000000231 Sesamum indicum Species 0.000 claims description 2
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 2
- 240000000785 Tagetes erecta Species 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 239000010495 camellia oil Substances 0.000 claims description 2
- 235000009120 camo Nutrition 0.000 claims description 2
- 235000021466 carotenoid Nutrition 0.000 claims description 2
- 150000001747 carotenoids Chemical class 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- 235000005607 chanvre indien Nutrition 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims description 2
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 claims description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 2
- 229960002852 ellagic acid Drugs 0.000 claims description 2
- 235000004132 ellagic acid Nutrition 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 150000002339 glycosphingolipids Chemical class 0.000 claims description 2
- 239000011487 hemp Substances 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 2
- 235000020232 peanut Nutrition 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- 229940068041 phytic acid Drugs 0.000 claims description 2
- 235000002949 phytic acid Nutrition 0.000 claims description 2
- 239000000467 phytic acid Substances 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 229940075420 xanthine Drugs 0.000 claims description 2
- 244000098338 Triticum aestivum Species 0.000 claims 2
- 230000002500 effect on skin Effects 0.000 claims 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 241000532749 Cholus Species 0.000 claims 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
- 239000007854 depigmenting agent Substances 0.000 claims 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
- 239000000700 radioactive tracer Substances 0.000 description 29
- 210000003491 skin Anatomy 0.000 description 29
- AJIMMVOZOJXJKD-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-n-(3,3',6'-trihydroxyspiro[3h-2-benzofuran-1,9'-xanthene]-5-yl)benzamide Chemical compound C1=C2C(O)OC3(C4=CC=C(O)C=C4OC4=CC(O)=CC=C43)C2=CC=C1NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F AJIMMVOZOJXJKD-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 24
- 238000009472 formulation Methods 0.000 description 16
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 16
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 16
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 14
- 239000008347 soybean phospholipid Substances 0.000 description 14
- 230000008595 infiltration Effects 0.000 description 13
- 238000001764 infiltration Methods 0.000 description 13
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 12
- 241000209140 Triticum Species 0.000 description 12
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000003833 cell viability Effects 0.000 description 11
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 10
- 229920000289 Polyquaternium Polymers 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000013024 dilution buffer Substances 0.000 description 8
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 8
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 8
- 229960002216 methylparaben Drugs 0.000 description 8
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 8
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 8
- 229960003415 propylparaben Drugs 0.000 description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 7
- 108090000426 Caspase-1 Proteins 0.000 description 7
- 102100035904 Caspase-1 Human genes 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000005538 encapsulation Methods 0.000 description 7
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 7
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 7
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 7
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000004927 skin cell Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- 229960005323 phenoxyethanol Drugs 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940067596 butylparaben Drugs 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 210000002768 hair cell Anatomy 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- OYINQIKIQCNQOX-UHFFFAOYSA-M 2-hydroxybutyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCC(O)C[N+](C)(C)C OYINQIKIQCNQOX-UHFFFAOYSA-M 0.000 description 4
- 102000004125 Interleukin-1alpha Human genes 0.000 description 4
- 108010082786 Interleukin-1alpha Proteins 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- KZENBFUSKMWCJF-UHFFFAOYSA-N [5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol Chemical compound S1C(CO)=CC=C1C1=CC=C(C=2SC(CO)=CC=2)O1 KZENBFUSKMWCJF-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- HJVCHYDYCYBBQX-HLTLHRPFSA-N (2s,3s,4e,6e,8s,9s)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid Chemical compound OC(=O)[C@@H](C)[C@@H](N)/C=C/C(/C)=C/[C@H](C)[C@@H](OC)CC1=CC=CC=C1 HJVCHYDYCYBBQX-HLTLHRPFSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 229920000688 Poly[(2-ethyldimethylammonioethyl methacrylate ethyl sulfate)-co-(1-vinylpyrrolidone)] Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010070835 Skin sensitisation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- KMQAPZBMEMMKSS-UHFFFAOYSA-K calcium;magnesium;phosphate Chemical compound [Mg+2].[Ca+2].[O-]P([O-])([O-])=O KMQAPZBMEMMKSS-UHFFFAOYSA-K 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 150000004985 diamines Chemical class 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- PBLZLIFKVPJDCO-UHFFFAOYSA-N omega-Aminododecanoic acid Natural products NCCCCCCCCCCCC(O)=O PBLZLIFKVPJDCO-UHFFFAOYSA-N 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 231100000370 skin sensitisation Toxicity 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- PHOLIFLKGONSGY-CSKARUKUSA-N (e)-(3-methyl-1,3-benzothiazol-2-ylidene)hydrazine Chemical compound C1=CC=C2S\C(=N\N)N(C)C2=C1 PHOLIFLKGONSGY-CSKARUKUSA-N 0.000 description 2
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- WJYIASZWHGOTOU-UHFFFAOYSA-N Heptylamine Chemical compound CCCCCCCN WJYIASZWHGOTOU-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 229940071160 cocoate Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 230000035614 depigmentation Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000399 optical microscopy Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 1
- ZQCIPRGNRQXXSK-UHFFFAOYSA-N 1-octadecoxypropan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(C)O ZQCIPRGNRQXXSK-UHFFFAOYSA-N 0.000 description 1
- JHRHFFULXFLTPE-UHFFFAOYSA-N 1-propan-2-yloxyhexadecan-2-ol Chemical compound CCCCCCCCCCCCCCC(O)COC(C)C JHRHFFULXFLTPE-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- VOZKAJLKRJDJLL-UHFFFAOYSA-N 2,4-diaminotoluene Chemical group CC1=CC=C(N)C=C1N VOZKAJLKRJDJLL-UHFFFAOYSA-N 0.000 description 1
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- BJRXGOFKVBOFCO-UHFFFAOYSA-N 2-hydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(C)O BJRXGOFKVBOFCO-UHFFFAOYSA-N 0.000 description 1
- VFKZECOCJCGZQK-UHFFFAOYSA-M 3-hydroxypropyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCCO VFKZECOCJCGZQK-UHFFFAOYSA-M 0.000 description 1
- MTYHUTYJKFVTJJ-UHFFFAOYSA-N 4-hydroxypyrene-1,2,3-trisulfonic acid Chemical compound OS(=O)(=O)C1=C(S(O)(=O)=O)C(S(O)(=O)=O)=C2C(O)=CC3=CC=CC4=CC=C1C2=C34 MTYHUTYJKFVTJJ-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101100345727 Medicago sativa MMK2 gene Proteins 0.000 description 1
- JQVDAXLFBXTEQA-UHFFFAOYSA-N N-butyl-butylamine Natural products CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 1
- 101800001775 Nuclear inclusion protein A Proteins 0.000 description 1
- 101800001776 Nuclear inclusion protein B Proteins 0.000 description 1
- 231100000107 OECD 471 Bacterial Reverse Mutation Test Toxicity 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920000691 Poly[bis(2-chloroethyl) ether-alt-1,3-bis[3-(dimethylamino)propyl]urea] Polymers 0.000 description 1
- 101710196222 Protein 4.3 Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- CFEPRLLVDYTTJT-UHFFFAOYSA-N [Na].[Na].[Na].NN Chemical compound [Na].[Na].[Na].NN CFEPRLLVDYTTJT-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940100539 dibutyl adipate Drugs 0.000 description 1
- 239000003989 dielectric material Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000010799 enzyme reaction rate Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012184 mineral wax Substances 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N mono-n-propyl amine Natural products CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- GMTCPFCMAHMEMT-UHFFFAOYSA-N n-decyldecan-1-amine Chemical compound CCCCCCCCCCNCCCCCCCCCC GMTCPFCMAHMEMT-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical group 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 229940078491 ppg-15 stearyl ether Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003139 primary aliphatic amines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003891 promutagen Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940097319 quaternium-22 Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
- 239000004520 water soluble gel Substances 0.000 description 1
- 229940084883 wheat amino acids Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
- A61K8/8182—Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
- A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/42—Colour properties
- A61K2800/43—Pigments; Dyes
- A61K2800/434—Luminescent, Fluorescent; Optical brighteners; Photosensitizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/54—Polymers characterized by specific structures/properties
- A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
- A61K2800/5426—Polymers characterized by specific structures/properties characterized by the charge cationic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
- A61Q1/06—Lipsticks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
프로브 명칭 | 특징 | Exc/Em | 농도 | 캡슐화여부 | 누수 | 세포투과 | 독성 | 리포좀 내 침투 | 보유(retained) |
#L7545L Lysosensor yellow/blue DND 160 | pH에민감함 | 329/440 | 10μM | Y | Y | Y | N | N | N |
#H-348 hydroxypyrene trisulfonic acid, trisodium salt | 403/511 | 1mM | N | NT | N | NT | N | N | |
#P-12925 pentafluorobenzoylamino fluorescein | 492/516 | 200μM | Y | N | N | Y | Y | ||
#F-1200 Fura-2.pentapotassium salt | Ca2+민감 | 335/505 | 10μM | N | N | N | N | Y | |
#C-369 carboxy dichlorofluorescein | 에스터라아제가 있는 경우 형광을 띰 | 85μM | Y | Y | Y | NT | NT | N | |
#B-1151 carboxyethyl carboxyfluorescein | 482/520 | 50μM | N | NT | ? | NT | NT | N | |
#T-490 tetramethylrhodamine isothiocyanate TRITC | 555/580 | Y | ? | ? | N | Y | PEI의 방해 없음 | ||
#C-687 cascade blue hydrazine trisodium salt | 399/421 | 200μM | Y | NT | N | N | Very low | N | |
#S-1129 sulfo fluorescein diacetate | 200μM | NT | NT | N | N | Very low | N | ||
#D-3329 dextran texas red | 592/609 | NT | NT | N | Y | N | N |
세포독성(무처리 대조군에 대한 %) | 침투(프로브 없음) | 침투(세척 후 형광) | |
PFB-F(485-530) | 110.7% | 8(45 증가) | 65(45 증가) |
TRITC(530-620) | 74.8 | 295(50 증가) | 1,119(50 증가) |
물질 | 농도 | 방출: 평균 | 방출: 표준편차 |
Triton X-100 | 3%1%0.5%0.1% | 44027458004083419829 | 177288839103 |
SDS | 3%1%0.5%0.1% | 62481718097667622990 | 1801558200108 |
NaCl | 200mM150mM100mM50mM | 68527762263145680 | 20403611362 |
pH | 9876 | 252651881687817640 | 4112267055 |
PEI의 농도(μM) | 0 | 1 | 10 | 50 | 100 |
생산량(%) | 89.0 | 92.3 | 91.0 | 87.5 | 86.3 |
PEI 농도 | 0 | 5μM | 10μM | 50μM | ||||
시간 | 평균 | 표준편차 | 평균 | 표준편차 | 평균 | 표준편차 | 평균 | 표준편차 |
2h | 6 | 0 | 49 | 4 | 67 | 7 | 116 | 6 |
4h | 7 | 3 | 63 | 5 | 89 | 9 | 159 | 10 |
6h | 6 | 0 | 65 | 10 | 94 | 13 | 203 | 12 |
24h | 9 | 3 | 120 | 5 | 129 | 3 | 291 | 17 |
48h | 6 | 1 | 160 | 18 | 171 | 13 | 306 | 6 |
시간 | 0 | 5 μM | 10μM | 50μM | PEI50 생존능 |
2h | 0.7 | 5.4 | 7.4 | 12.9 | 93.8% |
4h | 0.8 | 7.0 | 9.9 | 17.7 | 92.4% |
6h | 0.7 | 7.2 | 10.4 | 22.6 | 83.9% |
24h | 1.0 | 13.3 | 14.3 | 32.3 | 72.6% |
48h | 0.7 | 17.8 | 19.0 | 34.0 | 48.4% |
25 kDa PEI | 0 | 10μM | 50μM | 100μM |
총 단백질(㎍/mL) | 132.8 | 136.2 | 119.5 | 79.2 |
IL1(pg/mL) | 9.2 | 12.7 | 13.1 | 14.4 |
단백질 내 IL1(pg/mL) | 69.3 | 93.2 | 109.6 | 181.8 |
촉진지수 | 1 | 1.3 | 1.6 | 2.6 |
INCI 명칭 | 촉진지수 | 생존능 | 관찰여부 |
폴리에틸렌이민 25kDa | 34.7 | 74.1 | + |
코코디모니움 하이드록시프로필 가수분해된 밀 단백질 | 4.3 | 86 | - |
코코디모니움 하이드록시프로필 가수분해된 벼 단백질 | 18 | 85 | - |
스테아디모니움 하이드록시프로필 가수분해된 밀 단백질 | 4.6 | 86.4 | - |
로릴디모니움 하이드록시프로필 가수분해된 밀 단백질 | 6.2 | 87.5 | - |
하이드록시프로필트리모니움 가수분해된 밀 단백질 | 1.3 | 91.7 | - |
하이드록시프로필트리모니움 벌꿀(honey) | 15 | 92 | - |
소듐 라우로일 귀리 아미노산 | 0.8 | 76.6 | - |
소듐 라우로일 밀 아미노산 | 1.1 | 46.1 | - |
코코아민 | 32.7 | 79.7 | + |
라우릴디모니움 하이드록시프로필 가수분해된 대두 단백질 | 38.8 | 87.9 | + |
키토산 | 10.3 | 99 | - |
하이드록시프로필 구아 하이드록시프로필트리모니움 클로라이드 | 1.1 | 74.8 | - |
하이드록시프로필 구아 | -0.2 | 91.1 | - |
하이드록시프로필 구아 | -0.4 | 97.5 | - |
하이드록시프로필 구아 하이드록시프로필트리모니움 클로라이드 | 1.4 | 71.2 | - |
구아 하이드록시프로필트리모니움 | 0.6 | 53.3 | - |
메이프로 | 1 | 91.6 | - |
폴리쿼터니움 7 | 0.3 | 80.1 | - |
폴리비닐피롤리돈(1) | 1.4 | 85.1 | - |
폴리비닐카프로락탐 | 4.1 | 0 | - |
폴리비닐피롤리돈(2) | 0.7 | 26.6 | - |
폴리비닐피롤리돈(3) | 0.7 | 71 | - |
폴리쿼터니움 16(1) | 4.6 | 83.5 | - |
폴리쿼터니움 11(1) | 1.5 | 49.7 | - |
코코트리모니움 메토설페이트 | 0.1 | 55 | - |
폴리쿼터니움 16(2) | 8.4 | 33.8 | - |
폴리쿼터니움 16(3) | 1 | 38.8 | - |
폴리쿼터니움 16(4) | 12.5 | 67.1 | - |
폴리쿼터니움 16(5) | 0.2 | 85.3 | - |
폴리쿼터니움 44 | 0.8 | 59.7 | - |
코코알코니움 클로라이드 | 5.6 | 36.3 | - |
코코트리모니움 클로라이드 | -0.2 | 65.6 | - |
테트라하이드록시프로필 에틸렌디아민 | 1.9 | 95.3 | - |
스테라미도프로필 세테아릴 디모니움 토실레이트 및 PG | 13.1 | 93.2 | - |
쿼터니움 70 및 PG | -0.2 | 63.9 | - |
쿼터니움 26 | 30.9 | 59.2 | - |
쿼터니움 22 | 2 | 98.9 | - |
폴리코터니움 28 | 0.6 | 79.3 | - |
폴리쿼터니움 11(2) | 2.9 | 50.7 | - |
폴리쿼터니움 11(3) | 2.9 | 77.1 | - |
폴리쿼터니움 2 | 4.2 | 23.6 | - |
스테랄코니움 클로라이드 | 17.6 | 37.4 | - |
프로필아민 C3 | 0.9 | 103.3 | - |
n-부틸아민 C4 | 1.4 | 106.2 | - |
디부틸아민 2 C4 | 0.7 | 75.7 | - |
헥실아민 C6 | 0.2 | 82.1 | - |
헵틸아민 C7 | 3.7 | 39.4 | - |
디옥틸아민 2 C8 | 1 | 34.7 | - |
INCI 명칭 | 촉진지수 | 생존능 | 관찰 |
데실아민 C10 | 39.6 | 68.5 | + |
디데실아민 2 C10 | 1.2 | 28.3 | - |
운데실아민 C11 | 95.3 | 84 | + |
도데실아민 C12 | 47.1 | 57 | + |
트리데실아민 C13 | 44.5 | 62.6 | + |
테트라데실아민 C14 | 11.6 | 54.8 | - |
펜타데실아민 C15 | 14.9 | 73 | - |
옥타데실아민 C18 | 19.6 | 61.2 | - |
올레일아민 C18:1 | 1.9 | 87.1 | - |
1개의 알킬 지방사슬을 포함하는 1기 모노아민의 탄소 수 | 촉진지수 |
25 kDa PEI 대조군 | 34.7 |
C3 | 0.9 |
C4 | 1.4 |
C6 | 0.2 |
C7 | 3.7 |
C10 | 39.6 |
C11 | 95.3 |
C12 | 47.1 |
C13 | 44.5 |
C14 | 11.6 |
C15 | 14.9 |
C18 | 19.6 |
아민의 알킬 사슬의 수(사슬 길이) | 촉진지수 |
25 kDa PEI | 34.7 |
1(C4) | 1.7 |
2(C4) | 0.7 |
1(C10) | 39.6 |
2(C10) | 1.2 |
상품화된 4분자 물질 | 화학명 | 회사명 |
밀 | 코코디모니움, 스테아디모니움, 하이드록시프로필트리모니움 또는 로릴디모니움 가수분해된 밀 단백질, 밀 배아-아미도프로팔코니움 클로라이드 | Croda |
대두 | 로릴디모니움 하이드록시프로필 가수분해된 대두 단백질, 코코디모니움 하이드록시프로필 가수분해된 대두 단백질, 하이드록시프로필 트리메틸 암모늄 클로라이드 가수분해된 대두 단백질, 대두 디하이드록시프로필디모니움 글루코시드 | CrodaRITA corporation |
케라틴 | 하이드록시프로필트리모니움 가수분해된 케라틴 | RITA corporation |
카제인 | 하이드록시프로필트리모니움 가수분해된 카제인 | RITA corporation |
콜라겐 | 하이드록시프로필트리모니움 가수분해된 콜라겐, 로릴디모니움 하이드록시프로필 가수분해된 콜라겐 | RITA corporationCognis |
실크 | 하이드록시프로필트리모니움 가수분해된 실크 | RITA corporation |
벼 | 코코디모니움 하이드록시프로필 가수분해된 벼 단백질 | Sochibo |
구아 | 하이드록시프로필 구아 하이드록시프로필트리모니움 클로라이드, 하이드록시프로필 구아 하이드록시프로필트리모니움 클로라이드, 구아 하이드록시프로필트리모니움 | MeyhallRhodia |
벌꿀 | 하이드록시프로필트리모니움 벌꿀(honey) | ARCH |
셀룰로우즈 | 폴리쿼터니움 4 및 10폴리쿼터니움 39 | Quimasso |
4분자 대두(%) | 0.5 | 1 | 1.5 | 2 | 2.5 |
촉진지수 | 0.6 | 1.6 | 38.9 | 97.2 | 99.9 |
세포 생존능(%) | 92.4 | 97.9 | 87.9 | 75.4 | 77.3 |
기능성 물질의 농도 | 50μM PEI | 0.5% 대두 | 1% 대두 | 1.5% 대두 | 2% 대두 |
PNPP | 72.3 | 91.8 | 91.6 | 87.5 | 88.4 |
IL1 알파 | 350 | 137.5 | 137.5 | 212.5 | 187.5 |
IL1 알파/PNPP | 484.1 | 149.8 | 150.1 | 242.9 | 212.1 |
기능성 물질의 농도 | 50μM PEI | 0.5% 대두 | 1% 대두 | 1.5% 대두 | 2% 대두 |
PNPP | 59.8 | 91.8 | 91.6 | 87.5 | 88.5 |
카스파아제-1 | 642.8 | 76 | 87.7 | 78.3 | 117.5 |
카스파아제-1/PNPP | 1074.9 | 82.8 | 95.7 | 89.5 | 132.8 |
I | NI | A=I/NI | B=리포좀/대조군 | C=리포좀/자유형 | |
본 발명 물질 | 118990 | 58786 | 2.01 | 79.3% | +23% |
비기능성 리포좀 | 114907 | 52306 | 2.31 | 91.1% | +11% |
리포좀 PEI | 105257 | 40148 | 2.82 | 111.4% | -9% |
자유형 | 리포좀 | PEI 리포좀 | 대두 리포좀 | |
알부틴 | 0.004 | 0.001 | 0 | 0 |
Phytolight® | 0.01 | 0.008 | 0.003 | 0.0016 |
카테킨 | 0.007 | 0.007 | 0 | 0.003 |
자유형 | 리포좀 | 4분자 리포좀 | |
확산 | 0.57±0.03 | 1.17±0.05 | 1.76±0.13 |
방출 24h | 0.691±0.06 | 1.398±0.07 | 1.77±0.21 |
저장 | 0.81±0.1 | 1.27±0.17 | 2.61±0.33 |
Claims (31)
- 수화층판상 혹은 리포좀 내에 내재하거나 운반되는 적어도 하나의 활성성분의 세포 내 침투를 촉진할 수 있는 물질 혹은 그것들의 혼합물을 자체 구조 내에 포함하고 있으며, 상기 물질은 다음의 군에서 선택됨을 특징으로 하는 수화층판상 혹은 리포좀:a) 폴리에틸렌이민,b) C10과 C18 사이에 탄소사슬을 갖는 1기, 2기, 3기 또는 4기 지방족 모노아민, 유리하게는 한 개의 C10-C18 지방사슬을 포함하는 모노아민, 바람직하게는 한 개의 C10-C18 지방사슬을 포함하는 1기 또는 4기 모노아민,c) 양이온성 중합체, 특히 양이온성 천연 중합체 또는 선택적으로 양이온을 띠는 중합체 또는 양이온성 합성 중합체,단, 상기 수화층판상 혹은 리포좀은 세포 내 침투 시 반드시 활성이 없는 형광물질, 예를 들어 펜타플루오로벤조일아미노 플루오레신(pentafluorobenzoylamino fluorescein)을 선택적으로 적어도 하나 포함하고, 이러한 침투는 가시적으로 볼 수 있음.
- 제 1항에 있어서, 선택적으로 양이온성 천연 중합체는 키토산, 4분자의 벌꿀 중합체, 밀 단백질 또는 4분자의 밀 단백질, 벼 단백질 또는 4분자의 벼 단백질, 콩 단백질 또는 4분자의 콩 단백질, 콜라겐 또는 4분자의 콜라겐, 케라틴 또는 4분자의 케라틴, 카제인 또는 4분자의 카제인, 4분자의 셀룰로우즈 또는 4분자의 구아(guar)로 구성된 군에서 선택됨을 특징으로 하는 수화층판상 혹은 리포좀.
- 제 1항에 있어서, 1기 모노아민은 데실아민, 운데실아민, 도데실아민, 트리데실아민, 테트라데실아민, 펜타데실아민, 옥타데실아민으로 구성된 군에서 선택되거나 또는 C8과 C18 사이에 탄화수소 사슬을 갖는 코프라(copra) 아민 혼합물과 같은 1기 모노아민의 혼합물임을 특징으로 하는 수화층판상 혹은 리포좀.
- 상기 전항들 중 어느 한 항에 있어서, 폴리에틸렌이민을 포함함을 특징으로 하는 수화층판상 혹은 리포좀.
- 상기 전항들 중 어느 한 항에 있어서, 수화층판상 혹은 리포좀은 지질상에서 리포좀막을 변형시키는 제제, 예를 들어 트리글리세라이드, 극성 인지질 또는 극성 스핑고리피드로 구성된 군에서 단독 또는 그것의 혼합물로서 선택되는 극성지질을 적어도 하나 포함함을 특징으로 하는 수화층판상 혹은 리포좀.
- 제 5항에 있어서, 상기 극성 인지질은 포스파티딜콜린 또는 레시틴, 포스파티딜에타놀아민 또는 세팔린, 포스파티딜세린, 포스파티딜글리세롤, 디포스파티딜글리세롤 또는 카디오리핀, 포스파티딜이노시톨로 구성된 군에서 단독 또는 그것의 혼합물로서 선택됨을 특징으로 하는 수화층판상 혹은 리포좀.
- 제 5항 또는 제 6항에 있어서, 극성 스핑고리피드는 세라마이드, 스핑고포스포리피드, 글리코스핑고리피드로 구성된 군에서 단독 또는 그것의 혼합물로서 선택됨을 특징으로 하는 수화층판상 혹은 리포좀.
- 상기 전항들 중 어느 한 항에 있어서, 수화층판상 혹은 리포좀은 지질상에 천연소재에서 추출된 레시틴을 적어도 하나 포함하며, 상기 천연소재는 대두, 포도, 해바라기, 루핀, 땅콩, 참깨, 서양호박, 브랜 오일(bran oil), 동백오일, 금잔화, 아마 및 대마로 구성된 군에서 단독 또는 그것의 혼합물로서 선택됨을 특징으로 하는 수화층판상 혹은 리포좀.
- 상기 전항들 중 어느 한 항에 있어서, 수화층판상 혹은 리포좀은 지질상에 막을 견고하게 하는 제제로서 콜레스테롤 또는 콜레스테릴헤미석시네이트를 포함함을 특징으로 하는 수화층판상 혹은 리포좀.
- 상기 전항들 중 어느 한 항에 있어서, 수화층판상 혹은 리포좀은 지질상에 수화층판상 혹은 리포좀의 막을 유동화하는 제제로서 계면활성제를 적어도 하나 포함함을 특징으로 하는 수화층판상 혹은 리포좀.
- 상기 전항들 중 어느 한 항에 있어서, 상기 수화층판상 혹은 리포좀을 포함하는 조성물 중량당 0.01%의 5-펜타플루오벤조일아민을 포함하며, 세포 내 침투 시 반드시 활성이 없는 형광물질 또는 형광성분을 포함함을 특징으로 하는 수화층판상 혹은 리포좀.
- 상기 전항들 중 어느 한 항에 있어서, 세포 내 침투를 촉진하는 물질의 농도는 수화층판상 혹은 리포좀을 포함하는 조성물의 중량당 0.05∼25%임을 특징으로 하는 수화층판상 혹은 리포좀.
- 상기 전항들 중 어느 한 항에 있어서, 세포 내 침투를 촉진하는 물질의 농도는 수화층판상 혹은 리포좀을 포함하는 조성물의 중량당 0.5∼2.5%임을 특징으로 하는 수화층판상 혹은 리포좀.
- 상기 전항들 중 어느 한 항에 있어서, 상기 지방족 모노아민은 C10과 C13 사이에 탄소사슬로 연결됨을 특징으로 하는 수화층판상 혹은 리포좀.
- 상기 전항들 중 어느 한 항에 있어서, 상기 지방족 모노아민은 C10과 C18, 바람직하게는, C10과 C13 사이에 지방족 탄소사슬을 한 개 포함하는 1기 모노아민의 4분자 형태임을 특징으로 하는 수화층판상 혹은 리포좀.
- 상기 전항들 중 어느 한 항에 있어서, 1기 모노아민은 4분자 형태이며, R-N(R1R2R3) 이 4개가 연결되어 있으며, 식물 단백질 용액, 바람직하게는 대두 단백질에서 선택되며, 단, R은 가수분해되거나 혹은 그렇지 않은, 하이드록시알킬화된, 특히 하이드록시프로필화되거나 혹은 그렇지 않은 식물 단백질을 나타내며, R1 및 R2는 각각 C1-C6 탄화수소군, 바람직하게는 메틸 혹은 에틸을, R3는 10∼18 탄소를 갖는 알킬 레디칼, 주로 12개의 탄소(lauryl)를 갖는 알킬 레디칼을 나타냄을 특징으로 하는 수화층판상 혹은 리포좀.
- 상기 전항들 중 어느 한 항에 있어서, 수화층판상 혹은 리포좀에 내재하거나 또는 운반되는 물질 혹은 활성성분은 비타민 E, 플라보노이드, 카로티노이드, 비타민 C, 혹은 그들의 유도체와 같은 항-라디칼 제제, 카테킨, 하이드로퀴논, 아부틴, 파이트산(phytic acid), 엘라그산(ellagic acid), 비타민 C, 혹은 그들의 유도체와 같은 탈색소제, 잔틴과 같은 슬리밍제, 티로신, 트립토판, 페닐알라닌, 콜레우스 추출물 혹은 그들의 유도체와 같은 피부 혹은 모발 염색제로 구성된 군에서 선택됨을 특징으로 하는 수화층판상 혹은 리포좀.
- 세포 내 침투를 촉진하는 물질을 적어도 하나 포함하는 수화층판상 혹은 리포좀을 포함하며, 상기 전항들 중 어느 한 항에서 정의되는 상기 수화층판상 혹은 리포좀 및 세포 내 침투를 촉진하는 상기 물질은 화장료에 적합한 부형제와 혼합됨을 특징으로 하는 화장료 혹은 피부용 화장료 조성물.
- 세포 내 침투를 촉진하는 물질을 적어도 하나 포함하는 수화층판상 혹은 리포좀을 포함하며, 제 1항 내지 제 17항 중 어느 한 항에서 정의되는 상기 수화층판상 혹은 리포좀 및 세포 내 침투를 촉진하는 상기 물질은 약제학적으로 적합한 부형제와 혼합됨을 특징으로 하는 약제학적 혹은 피부용 약제학적 조성물.
- 제 19항에 있어서, 세포 내 침투를 촉진하는 물질의 농도는 최종 조성물의 중량당 0.05∼25%이며, 바람직하게는 0.5∼2.5%임을 특징으로 하는 약제학적 혹은 피부용 약제학적 조성물.
- 세포 내 침투를 촉진하는 물질을 포함하는 수화층판상 혹은 리포좀을 포함하고, 상기 물질과 수화층판상 혹은 리포좀은 제 1항 내지 제 17항 중 어느 한 항에서 정의됨을 특징으로 하는 주름예방효과, 항산화효과, 슬리밍효과, 미백효과, 피부 혹은 모발 염색효과가 있는 화장료 혹은 피부용 화장료 조성물.
- 제 18항, 20항 및 21항 중 어느 한 항에 기재된 화장료 혹은 피부화장료 조성물을 대상 피부 혹은 모발 부분에 처리하는 단계를 포함함을 특징으로 하는 코스메틱 케어방법.
- 제 22항에 있어서, 코스메틱 케어는 주름예방효과, 항산화효과, 슬리밍관리, 미백효과, 피부 혹은 모발 염색관리 중 어느 하나임을 특징으로 하는 코스메틱 케어방법.
- 화장품 주로 화장료 조성물의 제조, 주로 주름예방활성, 항산화활성, 슬리밍활성, 미백활성, 피부 혹은 모발 염색활성용 화장품으로서 제 1항 내지 제 17항 중 어느 한 항에 따른 수화층판상 혹은 리포좀의 이용.
- 다음을 포함함을 특징으로 하는 수화층판상 혹은 리포좀에 의해 운반되는 물질 혹은 활성성분의 세포 내 침투를 촉진할 수 있는 물질의 스크리닝 방법:a) 상기 수화층판상 혹은 상기 리포좀을 형성할 수 있는 물-지질 혼합물의 제조 단계;b) 상기 물-지질 혼합물에서 분산과정 전에, 세포 내 침투 시 바람직하게는 반드시 활성이 없는 형광물질을 결합시키는 단계;c) 상기 물-지질 혼합물에서 분산 전 또는 과정 중에, 세포 내 침투를 촉진할 수 있는 활성가능성이 있는 상기 물질로부터 선택되는 시험물질과 비교물질을 결합시키는 단계;d) 상기 b) 또는 c) 단계에서 얻은 물-지질 혼합물로부터 수화층판상 또는 리포좀을 형성하는 적당한 방법에 따라 상기 수화층판상 또는 상기 리포좀을 제조하는 단계; 및,e) 세포 내 형광을 측정하여 형광물질의 세포 내 침투를 측정하는 단계.
- 제 25항에 있어서, 형광물질의 세포 내 침투 결과는 비교물질 특히 폴리에틸렌이민에서 얻은 세포 내 침투와 비교함을 특징으로 하는 스크리닝 방법.
- 제 25항 또는 제 26항에 있어서, 주로 배양 섬유아세포, 바람직하게는 정상인간 섬유아세포에서 활성가능성이 있는 물질의 세포독성 및/또는 세포사멸(apoptosis)의 유도를 측정함을 특징으로 하는 스크리닝 방법.
- 제 25항 내지 제 27항 중 어느 한 항에 있어서, 세포 내 침투에 있어 반드시 활성이 없는 형광물질은 상기 배양 섬유아세포에 자발적으로 침투하지 않는 형광물질임을 특징으로 하는 스크리닝 방법.
- 제 25항 내지 제 28항 중 어느 한 항에 있어서, 상기 형광물질은 펜타플루오로벤조일아미노 플루오레신(pentafluorobenzoylamino fluorescein)을 포함하거나 또는 상기 물질이며, 세포 내 침투를 평가하는 데 이용되는 수화층판상 또는 리포좀을 포함하는 최종 조성물의 중량당 0.01% 의 농도로 이용됨을 특징으로 하는 스크리닝 방법.
- 제 25항 내지 제 29항 중 어느 한 항에 있어서, 상기 형광물질은 폴리에틸렌이민을 첨가한 상태에서 결합되며, 이때 형광물질과 폴리에틸렌이민은 세포독성이 없는 농도로 첨가됨을 특징으로 하는 스크리닝 방법.
- 제 25항 내지 제 29항 중 어느 한 항에 있어서, 세포 내 침투를 촉진할 수 있는 물질은 C10과 C18 사이에, 바람직하게는 C10에서 C13 사이에 알킬 사슬을 포함하는 1기 지방족 모노아민 또는 양이온성 중합체, 특히 선택적으로 양이온을 띠는 천연 중합체, 또는 제 1항 내지 제 17항 중 어느 한 항에 기재된 수화층판상 또는 리포좀에 결합되는 양이온성 합성 중합체 중에서 선택됨을 특징으로 하는 스크리닝 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0405640 | 2004-05-25 | ||
FR0405640A FR2870741B1 (fr) | 2004-05-25 | 2004-05-25 | Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant. |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050112498A true KR20050112498A (ko) | 2005-11-30 |
KR100697361B1 KR100697361B1 (ko) | 2007-03-20 |
Family
ID=33427722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040104333A KR100697361B1 (ko) | 2004-05-25 | 2004-12-10 | 세포 내 침투를 촉진하는 지방족 모노아민 또는 양이온성중합체를 포함하는 수화층판상 또는 리포좀, 그것의스크리닝 방법 및 이를 포함하는 화장료 혹은 약제학적조성물 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9655822B2 (ko) |
JP (2) | JP4950419B2 (ko) |
KR (1) | KR100697361B1 (ko) |
DE (1) | DE102004045186B9 (ko) |
ES (1) | ES2268946B2 (ko) |
FR (1) | FR2870741B1 (ko) |
GB (1) | GB2415375B (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180050003A (ko) * | 2016-11-04 | 2018-05-14 | 주식회사 자올 | 두피 침투력 효과가 증진된 탈모 방지 또는 모발성장 촉진 조성물을 포함하는 헤어팩 |
WO2023132553A1 (ko) * | 2022-01-06 | 2023-07-13 | 코스맥스 주식회사 | 피부 흡수 증진을 위한 양이온성 리포좀 및 이의 제조 방법 |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE038247T2 (hu) | 2004-05-19 | 2018-10-29 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | Nátrium-deoxikolátot tartalmazó injektálható készítmény |
US20060127468A1 (en) * | 2004-05-19 | 2006-06-15 | Kolodney Michael S | Methods and related compositions for reduction of fat and skin tightening |
US7754230B2 (en) * | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
JP2008094809A (ja) * | 2006-10-16 | 2008-04-24 | Kose Corp | リポソーム組成物およびそれを配合する化粧料、並びに皮膚外用剤 |
FR2911779B1 (fr) * | 2007-01-30 | 2009-04-24 | Lvmh Rech | Composition contenant un extrait d'ambre |
JP5196833B2 (ja) * | 2007-04-07 | 2013-05-15 | ヤヱガキ醗酵技研株式会社 | 機能性食品素材とその製造方法 |
CH715456B1 (de) | 2007-04-27 | 2020-04-30 | Mibelle Ag | Kosmetisches Produkt zur topischen Anwendung für den Schutz und die Erneuerung von Hautstammzellen, welches sich von dedifferenzierten Pflanzenzellen ableitet. |
KR101362619B1 (ko) * | 2008-02-20 | 2014-02-13 | 이엘씨 매니지먼트 엘엘씨 | 피부 미백용 국소 조성물 및 방법 |
US9445975B2 (en) | 2008-10-03 | 2016-09-20 | Access Business Group International, Llc | Composition and method for preparing stable unilamellar liposomal suspension |
JP5465182B2 (ja) * | 2008-10-14 | 2014-04-09 | 株式会社日本触媒 | ポリアルキレンイミンを含むウイルス感染症治療薬 |
WO2010092142A1 (de) | 2009-02-12 | 2010-08-19 | Rovi Cosmetics International Gmbh | Kationisches trägersystem aus positiv geladenen lipidvesikeln |
US8101593B2 (en) | 2009-03-03 | 2012-01-24 | Kythera Biopharmaceuticals, Inc. | Formulations of deoxycholic acid and salts thereof |
AR076062A1 (es) * | 2010-01-07 | 2011-05-18 | Lo Riggio Victor Pascual | Nanovector de carga positiva sustantivo al cabello y a la piel |
ES2373704B1 (es) * | 2010-02-18 | 2013-01-24 | Lipotec S.A. | Liposomas para el tratamiento de materiales textiles. |
EP2540311A4 (en) * | 2010-02-26 | 2016-07-06 | Univ Nagasaki | COMPOSITE BODY FOR RELEASING ANTIGENS OR MEDICAMENTS |
JPWO2011142484A1 (ja) * | 2010-05-14 | 2013-07-22 | 株式会社日本触媒 | ポリアルキレンイミンを含むウイルス感染症治療薬 |
BR112012029160A8 (pt) | 2010-05-18 | 2017-06-06 | Unilever Nv | Composições para clarear a pele, processo para preparar um extrato, uso de um extrato e método cosmético para clarear a pele |
WO2012093643A1 (ja) | 2011-01-05 | 2012-07-12 | 花王株式会社 | 化粧料 |
MX363465B (es) | 2011-02-18 | 2019-03-25 | Kythera Biopharmaceuticals Inc | Tratamiento de la grasa submental. |
US8653058B2 (en) | 2011-04-05 | 2014-02-18 | Kythera Biopharmaceuticals, Inc. | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
EP2961369B1 (en) * | 2013-04-02 | 2018-09-12 | Evonik Schlüchtern GmbH | Compositions of delivery systems and lupine with physical stability |
JP6169240B1 (ja) * | 2016-10-28 | 2017-07-26 | サンスター株式会社 | リノール酸含有組成物 |
US12013400B2 (en) | 2017-05-26 | 2024-06-18 | Gennext Technologies, Inc. | Radical dosimetry methods for in vivo hydroxyl radical protein foot-printing |
US12016688B2 (en) | 2017-05-26 | 2024-06-25 | Gennext Technologies, Inc. | In vivo radical dosimetry and in vivo hydroxyl radical protein foot-printing |
WO2019111415A1 (ja) | 2017-12-08 | 2019-06-13 | ワミレスコスメティックス株式会社 | カチオン化ベシクル及びその組成物 |
EP3906395A4 (en) * | 2019-01-04 | 2022-10-12 | GenNext Technologies, Inc. | IN VIVO RADICAL DOSIMETRY AND IN VIVO HYDROXYL RADICAL PROTEIN FOOT PRINTING |
JP2022525832A (ja) * | 2019-01-04 | 2022-05-20 | ジェネクスト テクノロジーズ インコーポレイテッド | 生体内ラジカル線量測定及び生体内ヒドロキシルラジカルのタンパク質フットプリント法 |
KR102223332B1 (ko) * | 2020-10-28 | 2021-03-08 | (주)캔디스피드코리아 | 리포좀 포장된 l-아르기닌 및 유기 지방산을 포함하는 염모제 조성물 |
JP7042998B1 (ja) | 2021-05-06 | 2022-03-29 | 正人 栗村 | ヘアカラー後処理方法 |
CN115015143A (zh) * | 2022-08-08 | 2022-09-06 | 山东省食品药品检验研究院 | 一种透皮吸收制剂中卡波姆均聚物的分析方法 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE43327T1 (de) * | 1980-07-01 | 1983-01-05 | L'Oreal, 75008 Paris | Verfahren zur herstellung stabiler dispersionen in einer waessrigen phase von mindestens einer fluessigen, nicht mit wasser mischbaren phase und die entsprechenden dispersionen. |
US4721612A (en) * | 1984-04-12 | 1988-01-26 | The Liposome Company, Inc. | Steroidal liposomes |
US4617186A (en) * | 1984-12-28 | 1986-10-14 | Alcon Laboratories, Inc. | Sustained release drug delivery system utilizing bioadhesive polymers |
US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
EP0198765A3 (en) | 1985-04-09 | 1987-10-21 | Georgetown University | Preparation of liposomes |
US5230899A (en) * | 1985-08-07 | 1993-07-27 | Smithkline Beecham Corporation | Methods and compositions for making liposomes |
FR2597367B1 (fr) | 1986-04-22 | 1988-07-15 | Oreal | Procede pour faciliter la formation de spherules lipidiques en dispersion dans une phase aqueuse et pour ameliorer leur stabilite et leur taux d'encapsulation, et dispersions correspondantes. |
US4921644A (en) * | 1988-02-29 | 1990-05-01 | Technology Unlimited, Inc. | Mucin directed lipsome |
AU612285B2 (en) * | 1988-10-05 | 1991-07-04 | Vestar, Inc. | Method of making liposomes with improved stability during drying |
US6177100B1 (en) * | 1988-12-02 | 2001-01-23 | L'oreal | Cosmetic or pharmaceutical composition for the treatment of the hair and scalp |
DE3935257A1 (de) | 1989-10-23 | 1991-04-25 | Langhals Heinz | Mit antikoerpern verknuepfte liposomen als traeger fuer einen gezielten transport von wirkstoffen und reagenzien - fluoreszenzmarkierung der transportwege und des wirkorts |
US5705187A (en) | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
FR2662605B1 (fr) * | 1990-05-31 | 1994-12-02 | Oreal | Composition cosmetique ou pharmaceutique pour le traitement des cheveux et du cuir chevelu. |
DE69116144T2 (de) * | 1991-02-14 | 1996-05-09 | Baxter Int | Bindung substratspezifischer affinitätssubstanzen an liposomen |
US5603872A (en) * | 1991-02-14 | 1997-02-18 | Baxter International Inc. | Method of binding recognizing substances to liposomes |
FR2673838B1 (fr) * | 1991-03-14 | 1995-03-03 | Oreal | Compositions cosmetiques contenant une dispersion de particules solides dont la surface est revetue a l'aide d'un polymere cationique. |
DE4111982C2 (de) * | 1991-04-12 | 1998-12-24 | Merz & Co Gmbh & Co | Stabile kleinpartikuläre Liposomenzubereitungen, deren Herstellung und Verwendung |
CA2115364A1 (en) * | 1991-08-16 | 1993-03-04 | Philip L. Felgner | Composition and method for treating cystic fibrosis |
KR100315213B1 (ko) * | 1993-04-02 | 2002-07-03 | 질레스피 카롤 | 리포좀생산방법 |
DE19505005C2 (de) * | 1995-02-15 | 1998-02-26 | Henkel Kgaa | Kationisierte pflanzliche Proteintenside |
US5869715A (en) * | 1995-09-27 | 1999-02-09 | The Reagents Of The University Of California | Polyfunctional cationic cytofectins |
DE19548853A1 (de) * | 1995-12-27 | 1997-07-03 | Abb Research Ltd | Kegelbrenner |
US6071535A (en) * | 1996-01-31 | 2000-06-06 | Collaborative Laboratories, Inc. | Lipid vesicles formed with alkylammonium fatty acid salts |
KR100220893B1 (ko) * | 1996-10-14 | 1999-09-15 | 허영섭 | 리포좀을 이용한 항생물질의 활성 측정방법 |
US5807957A (en) * | 1996-12-23 | 1998-09-15 | Macrochem Corporation | Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin |
FR2761886B1 (fr) | 1997-04-14 | 2000-05-05 | Virbac Sa | Compositions contenant au moins un polymere cationique et au moins une molecule active contenue dans au moins un vecteur micro ou nanoparticulaire, et leur utilisation pour le traitement de surfaces vivantes ou inertes |
FR2761912B1 (fr) | 1997-04-14 | 1999-07-02 | Capsulis | Procede destine a faire adherer un produit sur une surface |
US5962015A (en) * | 1997-05-02 | 1999-10-05 | Kobo Products S.A.R.L. | Stabilized liposomes |
JP3687277B2 (ja) * | 1997-06-10 | 2005-08-24 | サンスター株式会社 | 美白化粧料 |
US6958148B1 (en) * | 1998-01-20 | 2005-10-25 | Pericor Science, Inc. | Linkage of agents to body tissue using microparticles and transglutaminase |
WO2000003683A2 (en) | 1998-07-20 | 2000-01-27 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
US20020114829A1 (en) * | 1998-12-18 | 2002-08-22 | Hayat Onyuksel | Materials and methods for making improved liposome compositions |
US7780882B2 (en) * | 1999-02-22 | 2010-08-24 | Georgetown University | Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent |
GB9905136D0 (en) | 1999-03-06 | 1999-04-28 | Danbiosyst Uk | Surface modification of lamellar particles |
EP1173600A2 (en) | 1999-04-20 | 2002-01-23 | The University Of British Columbia | Cationic peg-lipids and methods of use |
DE19919634C2 (de) * | 1999-04-30 | 2001-06-07 | Aventis Pharma Gmbh | Test zur Bestimmung der Integrität komplexer Phospholipid/Lipid-Strukturen mit Hilfe synthetischer fluoreszenz-markierter Acylglyceride und dessen Anwendung zur Bestimmung der Aktivität von Lipasen |
US6277401B1 (en) * | 1999-05-07 | 2001-08-21 | U.S. Dermatologics, Inc. | Drug delivery device |
KR20010069179A (ko) | 1999-05-28 | 2001-07-23 | 박종상 | 유전자 전달용 양이온성 리피드 및 그 제조방법 |
US20020001613A1 (en) * | 2000-02-08 | 2002-01-03 | Susan Niemiec | Method of manufacturing liposomes |
FI111014B (fi) | 2000-07-03 | 2003-05-15 | Atso Raasmaja | Kationisten lipidien ja kationisten polymeerien synergiaan perustuva geenitransfektion menetelmä |
EP1138313A1 (de) | 2000-03-28 | 2001-10-04 | Primacare S.A. | Pro-liposomen |
US6696038B1 (en) * | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
EP1323415B1 (en) | 2000-10-04 | 2010-01-13 | Kyowa Hakko Kirin Co., Ltd. | Method of coating fine particle with lipid film |
DE10063433A1 (de) * | 2000-12-20 | 2002-06-27 | Henkel Kgaa | Verwendung von DNA-Reparatur-Enzymen als MMP-1-Inhibitoren |
US6979440B2 (en) * | 2001-01-29 | 2005-12-27 | Salvona, Llc | Compositions and method for targeted controlled delivery of active ingredients and sensory markers onto hair, skin, and fabric |
JP2004537501A (ja) | 2001-02-01 | 2004-12-16 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム | 肺への遺伝子送達のための安定化ポリマーエアロゾル |
FI113840B (fi) | 2001-03-26 | 2004-06-30 | Ctt Cancer Targeting Tech Oy | Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa |
DE10136483A1 (de) * | 2001-07-27 | 2003-02-13 | Cognis Deutschland Gmbh | Emulgator Gemisch |
KR100449889B1 (ko) * | 2001-08-30 | 2004-09-22 | 동국제약 주식회사 | 음이온 고분자와 인지질의 결합체가 함유된 인지질 리포좀및 그의 제조방법과 응용 |
DE10152145A1 (de) | 2001-10-19 | 2003-05-22 | Novosom Ag | Stabilisierung von Liposomen und Emulsionen |
WO2003038103A1 (en) | 2001-10-29 | 2003-05-08 | Atso Raasmaja | Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers |
EP1393719A1 (en) | 2002-08-23 | 2004-03-03 | Munich Biotech AG | Camptothecin-carboxylate formulations |
DE10231736A1 (de) | 2002-07-13 | 2004-02-12 | Merz Pharma Gmbh & Co. Kgaa | Vesikelbildende tensidhaltige Reinigungszubereitung mit hohem Wirkstoffanteil, Verfahren zu ihrer Herstellung sowie ihre Verwendung |
AR036316A1 (es) * | 2002-08-29 | 2004-08-25 | Monte Verde S A | Una composicion farmaceutica de liposomas de tamano pequeno y metodo de preparacion |
DE10243626A1 (de) * | 2002-09-19 | 2004-04-01 | Henkel Kgaa | Haarbehandlungsmittel enthaltend eine Wirkstoffkombination mit Liposomen |
US7785623B2 (en) * | 2002-10-01 | 2010-08-31 | Keller Brian C | Compositions and methods useful for the reduction of fine lines and wrinkles |
IL152609A0 (en) | 2002-11-03 | 2003-06-24 | Hapto Biotech Inc | Liposomal compositions comprising haptotactic peptides and uses thereof |
-
2004
- 2004-05-25 FR FR0405640A patent/FR2870741B1/fr not_active Expired - Lifetime
- 2004-06-30 US US10/880,810 patent/US9655822B2/en not_active Expired - Fee Related
- 2004-09-17 DE DE102004045186A patent/DE102004045186B9/de not_active Expired - Fee Related
- 2004-10-04 GB GB0422048A patent/GB2415375B/en not_active Expired - Fee Related
- 2004-12-10 KR KR1020040104333A patent/KR100697361B1/ko active IP Right Grant
- 2004-12-10 ES ES200402941A patent/ES2268946B2/es active Active
- 2004-12-22 JP JP2004370552A patent/JP4950419B2/ja active Active
-
2008
- 2008-10-16 JP JP2008267866A patent/JP5220546B2/ja active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180050003A (ko) * | 2016-11-04 | 2018-05-14 | 주식회사 자올 | 두피 침투력 효과가 증진된 탈모 방지 또는 모발성장 촉진 조성물을 포함하는 헤어팩 |
WO2023132553A1 (ko) * | 2022-01-06 | 2023-07-13 | 코스맥스 주식회사 | 피부 흡수 증진을 위한 양이온성 리포좀 및 이의 제조 방법 |
Also Published As
Publication number | Publication date |
---|---|
JP2009108056A (ja) | 2009-05-21 |
US9655822B2 (en) | 2017-05-23 |
DE102004045186B9 (de) | 2012-02-16 |
GB2415375A (en) | 2005-12-28 |
JP2005350445A (ja) | 2005-12-22 |
GB0422048D0 (en) | 2004-11-03 |
ES2268946A1 (es) | 2007-03-16 |
FR2870741B1 (fr) | 2008-03-14 |
JP4950419B2 (ja) | 2012-06-13 |
DE102004045186A1 (de) | 2005-12-22 |
FR2870741A1 (fr) | 2005-12-02 |
ES2268946B2 (es) | 2009-07-06 |
DE102004045186B4 (de) | 2011-08-18 |
JP5220546B2 (ja) | 2013-06-26 |
GB2415375B (en) | 2007-01-31 |
US20050266065A1 (en) | 2005-12-01 |
KR100697361B1 (ko) | 2007-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20050112498A (ko) | 세포 내 침투를 촉진하는 지방족 모노아민 또는 양이온성중합체를 포함하는 수화층판상 또는 리포좀, 그것의스크리닝 방법 및 이를 포함하는 화장료 혹은 약제학적조성물 | |
Manca et al. | Improvement of quercetin protective effect against oxidative stress skin damages by incorporation in nanovesicles | |
KR920009587B1 (ko) | 뽕나무의 추출물을 함유하는 조성물 | |
JP5721619B2 (ja) | 微生物マットに由来するエキソポリサッカライドを含む化粧用組成物およびその使用 | |
RU2125442C1 (ru) | Композиция для ухода за кожей и способ ухода за кожей | |
US20090104258A1 (en) | Use of tocopheryl phosphate as an agent for preventing or slowing down the appearance of the effects of skin ageing | |
JP5134005B2 (ja) | Dna損傷の抑制及び修復のための水溶性のホウレンソウ抽出物 | |
JP2004196763A (ja) | 水系媒質に不溶性の酵素を含む化粧用または皮膚薬用組成物およびその使用 | |
US20080269304A1 (en) | Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use | |
KR20000070718A (ko) | 유리 스핑고이드 염기 및 세라미드의 조합으로 이루어지는 조성물 및 그것의 사용 | |
CN102046178A (zh) | 用于皮肤护理的组合物和方法 | |
CA2138880A1 (fr) | Composition cosmetique pour le traitement simultane des couches superficielles et profondes de la peau, son utilisation | |
US20140107047A1 (en) | Cosmetic compositions for increasing bioavailability of active compounds | |
Izquierdo et al. | Comparative skin penetration profiles of formulations including ultradeformable liposomes as potential nanocosmeceutical carriers | |
ES2622114T3 (es) | Sustancia para restablecer una coexpresión y una interacción normales entre las proteínas LOX y NRAGE | |
CN101357113B (zh) | 长耳齿状藻的亲脂提取物在皮肤再生中的用途、组合物和使用该提取物的化妆方法 | |
Deshmukh et al. | Formulation and evaluation of solid–lipid nanoparticle based 0.1% Soy isoflavone dermal gels | |
KR20160045000A (ko) | 염모제용 액정 유화제 및 이를 포함하는 염모제 | |
KR20100057274A (ko) | 피부 미백용 화장료 조성물 | |
KR20150079710A (ko) | 베시클 조성물 및 그것을 배합한 피부 외용제 및 화장료 | |
JPH0873370A (ja) | カプセル入りの植物抽出物を含有する化粧用もしくは皮膚科用組成物 | |
KR102334971B1 (ko) | 밀배아 추출물을 포함하는 두피 및 모발 케어용 화장료 조성물 | |
WO2014094101A1 (pt) | Ingrediente protetor da barreira cutânea e formulação cosmética e/ou dermatológica contendo o mesmo | |
Rubio et al. | Influence of vehicles on antioxidant efficacy in hair | |
Dargitz et al. | Milk phospholipid's protective effects against UV damage in skin equivalent models |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130304 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140226 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150310 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160308 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170303 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180222 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190307 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20200226 Year of fee payment: 14 |